Philadelphia, PA - May 8, 2013 - Lannett Company, Inc. (NYSE MKT: LCI) today reported continued strong momentum, with sharply improved financial results for its fiscal 2013 third quarter ended March 31, 2013, compared with the prior year period.

Lannett Company, Inc. (NYSE MKT: LCI) today announced that it expects to report fiscal 2013 third quarter net sales of approximately $39 million and diluted earnings per share between $0.12 and $0.14.

Lannett Company, Inc. (NYSE MKT: LCI) today announced that the company will present at the Needham's 12th Annual Healthcare Conference on Wednesday, May 1, 2013, at 2:20 p.m.

Finally, Zacks reiterated its neutral rating on shares of Teva Pharmaceutical Industries Ltd. They have a $40.00 price target on that stock.

Lannett Company, Inc. is engaged in developing, manufacturing, marketing and distributing generic versions of branded pharmaceutical products.

Separately, analysts at Oppenheimer raised their price target on shares of Lannett Company Incorporated from $6.00 to $9.00 in a research note to investors on Friday, February 8th.

Supernus carries a Zacks Rank #3 (Hold). Other companies like Santarus, Inc. ( SNTS - Snapshot Report ) and Catalyst Pharmaceutical Partners Inc. ( CPRX - Snapshot Report ) look more attractive with a Zacks Rank #1 (Strong Buy).

Isis Pharma currently carries a Zacks Rank #2 (Buy). Stocks such as Lannett Company, Inc. ( LCI ) and Alkermes plc ( ALKS ) look equally attractive with a Zacks Rank #2.

Let's also take a look at hedge fund and insider activity in other stocks similar to SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).

Avanir currently carries a Zacks Rank #4 (Sell). Currently, companies like Lannett Company, Inc. ( LCI ), Santarus, Inc. ( SNTS ) and Catalyst Pharmaceutical Partners Inc. ( CPRX) look more attractive with a Zacks Rank #1 (Strong Buy).